Is 7.5 mg weekly a defensible maintenance dose for mazdutide?

Setup, so nobody has to ask: 7.5 mg · mazdutide.

I would like to set this up properly once, rather than adjust it repeatedly.

My budget is real but not tight, and my tolerance for uncertainty is low.

How would you structure this, and what thresholds would you set in advance?

7.5 mg a week is 1.071 mg a day averaged out and 390 mg over a year — but "defensible" is not a property of the number, it is a property of where the number came from. A maintenance dose is defensible when a trial randomised people to it and reported what happened, and indefensible when it was arrived at by interpolation between two doses that were studied. So the question to ask of 7.5 mg is which arm it corresponds to: if a programme ran 7.5 mg as a maintenance level, there is an efficacy figure, a tolerability figure and a discontinuation rate attached to it. If it sits between two studied levels, everything said about it is extrapolation, and the burden of that is on whoever proposed it. The other half of the arithmetic is supply: at 7.5 mg a week a 10 mg vial is 1.33 weeks and you will need about 39 of them a year, which is worth knowing before the dose is settled rather than after. Maintenance doses are set by a prescriber against an individual; nothing here is medical advice.

Start with what is being maintained — weight, glycaemia or both — because they have different dose-response curves.

The withdrawal trials — STEP-4 and SURMOUNT-4 — established what happens when treatment stops entirely. They did not evaluate dose reduction, so the evidence for a lower maintenance dose is inference rather than data.

Label titration ladders, structure only

Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.

The maintenance dose is not necessarily the same a year later, since the counter-regulatory response attenuates slowly if at all.

A noisy weight signal makes premature conclusions easy, in both directions.

The lowest dose that holds the result is the answer, and it is individual.

edited 17 Jun 2025 by fiadh_cronin — added the citation requested in comments

Answering this needs the reason for the current dose, since a dose chosen for loss and a dose chosen for maintenance are different decisions.

Glycaemic maintenance has a faster and cleaner signal than weight maintenance, particularly with continuous monitoring, which makes the downward search more tractable when glycaemia is the endpoint.

A downward search proceeds one step at a time with at least eight weeks at each level, because a weekly agent takes four to five weeks to reach the new steady state and then needs time for the trend to be readable.

The caveat is that dose reduction is a clinical decision and this is a description of a search strategy rather than a recommendation.

Glycaemic maintenance gives a faster signal than weight maintenance.

On the detail: any reduction takes four to five weeks to express itself, so the search proceeds in months.

Weight is a noisy signal. A rolling four-week average is the instrument; single weigh-ins after a dose reduction will show nothing interpretable.

Mechanically, maintenance and loss are different endpoints. Loss requires a sustained energy deficit; maintenance requires only that the counter-regulatory drive is offset, and that may need less exposure.

Dose-response for weight in the trial programmes was real but flattening at the upper end, which is consistent with a lower maintenance requirement.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Going back up after a short gap does not require re-titrating from the bottom.